-
1
-
-
4544285158
-
Long-term results and modeling to predict outcomes in recipients with HCV infection: Results of the NIDDK liver transplantation database
-
Charlton, M.; Ruppert, K.; Belle, S.H.; Bass, N.; Schafer, D.; Wiesner, R.H.; Detre, K.; Wei, Y.; Everhart, J. Long-term results and modeling to predict outcomes in recipients with HCV infection: Results of the NIDDK liver transplantation database. Liver Transplant. 2004, 10, 1120–1130.
-
(2004)
Liver Transplant
, vol.10
, pp. 1120-1130
-
-
Charlton, M.1
Ruppert, K.2
Belle, S.H.3
Bass, N.4
Schafer, D.5
Wiesner, R.H.6
Detre, K.7
Wei, Y.8
Everhart, J.9
-
2
-
-
0033807694
-
Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation
-
Berenguer, M.; Prieto, M.; Rayon, J.M.; Mora, J.; Pastor, M.; Ortiz, V.; Carrasco, D.; San Juan, F.; Burgueno, MD.; Mir, J.; et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000, 32, 852–858.
-
(2000)
Hepatology
, vol.32
, pp. 852-858
-
-
Berenguer, M.1
Prieto, M.2
Rayon, J.M.3
Mora, J.4
Pastor, M.5
Ortiz, V.6
Carrasco, D.7
San Juan, F.8
Burgueno, M.D.9
Mir, J.10
-
3
-
-
58849128803
-
The natural history of recurrent hepatitis C and what influences this
-
Gane, E.J. The natural history of recurrent hepatitis C and what influences this. Liver Transplant. 2008, 14 (Suppl. 2), S36–S44.
-
(2008)
Liver Transplant
, vol.14
, pp. S36-S44
-
-
Gane, E.J.1
-
4
-
-
0036207348
-
The association between hepatitis Cinfection and survival after orthotopic liver transplantation
-
Forman, L.M.; Lewis, J.D.; Berlin, J.A.; Feldman, H.I.; Lucey, M.R. The association between hepatitis Cinfection and survival after orthotopic liver transplantation. Gastroenterology 2002, 122, 889–896.
-
(2002)
Gastroenterology
, vol.122
, pp. 889-896
-
-
Forman, L.M.1
Lewis, J.D.2
Berlin, J.A.3
Feldman, H.I.4
Lucey, M.R.5
-
5
-
-
7244247475
-
Fibrosis progression after liver transplantation in patients with recurrent hepatitis C
-
Neumann, U.P.; Berg, T.; Bahra, M.; Seehofer, D.; Langrehr, J.M.; Neuhaus, R.; Radke, C.; Neuhaus, P. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J. Hepatol. 2004, 41, 830–836.
-
(2004)
J. Hepatol
, vol.41
, pp. 830-836
-
-
Neumann, U.P.1
Berg, T.2
Bahra, M.3
Seehofer, D.4
Langrehr, J.M.5
Neuhaus, R.6
Radke, C.7
Neuhaus, P.8
-
6
-
-
18444415726
-
Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients
-
Berenguer, M.; Prieto, M.; San Juan, F.; Rayon, J.M.; Martinez, F.; Carrasco, D.; Moya, A.; Orbis, F.; Mir, J.; Berenguer, J. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002, 36, 202–210.
-
(2002)
Hepatology
, vol.36
, pp. 202-210
-
-
Berenguer, M.1
Prieto, M.2
San Juan, F.3
Rayon, J.M.4
Martinez, F.5
Carrasco, D.6
Moya, A.7
Orbis, F.8
Mir, J.9
Berenguer, J.10
-
7
-
-
84876296995
-
Progression of liver fibrosis in post-transplant hepatitis C: Mechanisms, assessment and treatment
-
Berenguer, M.; Schuppan, D. Progression of liver fibrosis in post-transplant hepatitis C: Mechanisms, assessment and treatment. J. Hepatol. 2013, 58, 1028–1041.
-
(2013)
J. Hepatol
, vol.58
, pp. 1028-1041
-
-
Berenguer, M.1
Schuppan, D.2
-
8
-
-
0031783001
-
Predictors of patient and graft survival following liver transplantation for hepatitis C
-
Charlton, M.; Seaberg, E.; Wiesner, R.; Everhart, J.; Zetterman, R.; Lake, J.; Detre, K.; Hoofnagle, J. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998, 28, 823–830.
-
(1998)
. Hepatology
, vol.28
, pp. 823-830
-
-
Charlton, M.1
Seaberg, E.2
Wiesner, R.3
Everhart, J.4
Zetterman, R.5
Lake, J.6
Detre, K.7
Hoofnagle, J.8
-
9
-
-
68349128254
-
Early high peak hepatitis C viral load levels independently predict hepatitis C-related liver failure post-liver transplantation
-
Shackel, N.A.; Jamias, J.; Rahman, W.; Prakoso, E.; Strasser, S.I.; Koorey, D.J.; Crawford, M.D.; Verran, D.J.; Gallagher, J.; McCaughan, G.W. Early high peak hepatitis C viral load levels independently predict hepatitis C-related liver failure post-liver transplantation. Liver Transplant. 2009, 15, 709–718.
-
(2009)
Liver Transplant
, vol.15
, pp. 709-718
-
-
Shackel, N.A.1
Jamias, J.2
Rahman, W.3
Prakoso, E.4
Strasser, S.I.5
Koorey, D.J.6
Crawford, M.D.7
Verran, D.J.8
Gallagher, J.9
McCaughan, G.W.10
-
10
-
-
78751505015
-
Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection
-
Charlton, M.R.; Thompson, A.; Veldt, B.J.; Watt, K.; Tillmann, H.; Poterucha, J.J.; Heimbach, J.K.; Goldstein, D.; McHutchison, J. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 2011, 53, 317–324.
-
(2011)
Hepatology
, vol.53
, pp. 317-324
-
-
Charlton, M.R.1
Thompson, A.2
Veldt, B.J.3
Watt, K.4
Tillmann, H.5
Poterucha, J.J.6
Heimbach, J.K.7
Goldstein, D.8
McHutchison, J.9
-
11
-
-
78049470128
-
Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C
-
1585.e1–1585.e3
-
Fukuhara, T.; Taketomi, A.; Motomura, T.; Okano, S.; Ninomiya, A.; Abe, T.; Uchiyama, H.; Soejima, Y.; Shirabe, K.; Matsuura, Y.; et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010, 139, 1577–1585, 1585.e1–1585.e3.
-
(2010)
Gastroenterology
, vol.139
, pp. 1577-1585
-
-
Fukuhara, T.1
Taketomi, A.2
Motomura, T.3
Okano, S.4
Ninomiya, A.5
Abe, T.6
Uchiyama, H.7
Soejima, Y.8
Shirabe, K.9
Matsuura, Y.10
-
12
-
-
0242456078
-
Host and donor risk factors before and after liver transplantation that impact HCV recurrence
-
Berenguer, M. Host and donor risk factors before and after liver transplantation that impact HCV recurrence. Liver Transplant. 2003, 9, S44–S47.
-
(2003)
Liver Transplant
, vol.9
, pp. S44-S47
-
-
Berenguer, M.1
-
13
-
-
84885308430
-
Drug-drug interactions during antiviral therapy for chronic hepatitis C
-
Kiser, J.J.; Burton, J.R., Jr.; Everson, G.T. Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat. Rev. Gastroenterol. Hepatol. 2013, 10, 596–606.
-
(2013)
Nat. Rev. Gastroenterol. Hepatol
, vol.10
, pp. 596-606
-
-
Kiser, J.J.1
Burton, J.R.2
Everson, G.T.3
-
14
-
-
22844435314
-
Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C.
-
Bizollon, T.; Pradat, P.; Mabrut, J.Y.; Chevallier, M.; Adham, M.; Radenne, S.; Souquet, J.C.; Ducerf, C.; Baulieux, J.; Zoulim, F.; et al. Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C. Am. J. Transplant. 2005, 5, 1909–1913.
-
(2005)
Am. J. Transplant.
, vol.5
, pp. 1909-1913
-
-
Bizollon, T.1
Pradat, P.2
Mabrut, J.Y.3
Chevallier, M.4
Adham, M.5
Radenne, S.6
Souquet, J.C.7
Ducerf, C.8
Baulieux, J.9
Zoulim, F.10
-
15
-
-
46349089961
-
Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin
-
Berenguer, M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J. Hepatol. 2008, 49, 274–287.
-
(2008)
J. Hepatol
, vol.49
, pp. 274-287
-
-
Berenguer, M.1
-
16
-
-
53749103476
-
Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection.
-
Veldt, B.J.; Poterucha, J.J.; Watt, K.D.; Wiesner, R.H.; Hay, J.E.; Kremers, W.K.; Rosen, C.B.; Heimbach, J.K.; Charlton, M.R. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am. J. Transplant. 2008, 8, 2426–2433.
-
(2008)
Am. J. Transplant.
, vol.8
, pp. 2426-2433
-
-
Veldt, B.J.1
Poterucha, J.J.2
Watt, K.D.3
Wiesner, R.H.4
Hay, J.E.5
Kremers, W.K.6
Rosen, C.B.7
Heimbach, J.K.8
Charlton, M.R.9
-
17
-
-
84906303033
-
A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy
-
Burton, J.R., Jr.; O’Leary, J.G.; Verna, E.C.; Saxena, V.; Dodge, J.L.; Stravitz, R.T.; Levitsky, J.; Trotter, J.F.; Everson, G.T.; Brown, R.S.; et al. A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. J. Hepatol. 2014, 61, 508–514.
-
(2014)
J. Hepatol
, vol.61
, pp. 508-514
-
-
Burton, J.R.1
O’Leary, J.G.2
Verna, E.C.3
Saxena, V.4
Dodge, J.L.5
Stravitz, R.T.6
Levitsky, J.7
Trotter, J.F.8
Everson, G.T.9
Brown, R.S.10
-
18
-
-
84890558343
-
.
-
Coilly, A.; Roche, B.; Dumortier J.; Leroy, V.; Botta-Fridlund, D.; Radenne, S.; Pageaux, G.P.; Si-Ahmed, S.N.; Guillaud, O.; Antonini, T.M.; et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: A multicenter experience. J. Hepatol. 2014, 60, 78–86.
-
(2014)
J. Hepatol
, vol.60
, pp. 78-86
-
-
Coilly, A.1
Roche, B.2
Dumortier, J.3
Leroy, V.4
Botta-Fridlund, D.5
Radenne, S.6
Pageaux, G.P.7
Si-Ahmed, S.N.8
Guillaud, O.9
Antonini, T.M.10
-
19
-
-
84913529500
-
P1185 Interim SVR 12 results from the Telaprevir phase 3B REPLACE study in treatment-naive stable liver transplant patients with genotype 1 HCV infection
-
Forns, X.; Samuel, D.; Mutimer, D.; Fagiouli, M.; Navasa, M. P1185 Interim SVR 12 results from the Telaprevir phase 3B REPLACE study in treatment-naive stable liver transplant patients with genotype 1 HCV infection. J. Hepatol. 2014, 60 (Suppl. 1).
-
(2014)
J. Hepatol
, vol.60
-
-
Forns, X.1
Samuel, D.2
Mutimer, D.3
Fagiouli, M.4
Navasa, M.5
-
20
-
-
84879551010
-
Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation
-
Pungpapong, S.; Aqel, B.A.; Koning, L.; Murphy, J.L.; Henry, T.M.; Ryland, K.L.; Yataco, M.L.; Satyanarayana, R.; Rosser, B.G.; Vargas, H.E.; et al. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transplant. 2013, 19, 690–700.
-
(2013)
Liver Transplant
, vol.19
, pp. 690-700
-
-
Pungpapong, S.1
Aqel, B.A.2
Koning, L.3
Murphy, J.L.4
Henry, T.M.5
Ryland, K.L.6
Yataco, M.L.7
Satyanarayana, R.8
Rosser, B.G.9
Vargas, H.E.10
-
21
-
-
84904647749
-
ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection
-
Andreone, P.; Colombo, M.G.; Enejosa, J.V.; Koksal, I.; Ferenci, P.; Maieron, A.; Mullhaupt, B.; Horsmans, Y.; Weiland, O.; Reesink, H.W.; et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 2014, 147, 359.e351–365.e351.
-
(2014)
Gastroenterology
, vol.147
, pp. e351-e365
-
-
Andreone, P.1
Colombo, M.G.2
Enejosa, J.V.3
Koksal, I.4
Ferenci, P.5
Maieron, A.6
Mullhaupt, B.7
Horsmans, Y.8
Weiland, O.9
Reesink, H.W.10
-
22
-
-
84901036125
-
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.
-
Poordad, F.; Hezode, C.; Trinh, R.; Kowdley, K.V.; Zeuzem, S.; Agarwal, K.; Shiffman, M.L.; Wedemeyer, H.; Berg, T.; Yoshida, E.M.; et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N. Engl. J. Med. 2014, 370, 1973–1982.
-
(2014)
N. Engl. J. Med.
, vol.370
, pp. 1973-1982
-
-
Poordad, F.1
Hezode, C.2
Trinh, R.3
Kowdley, K.V.4
Zeuzem, S.5
Agarwal, K.6
Shiffman, M.L.7
Wedemeyer, H.8
Berg, T.9
Yoshida, E.M.10
-
23
-
-
84900339263
-
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.
-
Afdhal, N.; Zeuzem, S.; Kwo, P.; Chojkier, M.; Gitlin, N.; Puoti, M.; Romero-Gomez, M.; Zarski, J.P.; Agarwal, K.; Buggisch, P.; et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N. Engl. J. Med. 2014, 370, 1889–1898.
-
(2014)
N. Engl. J. Med.
, vol.370
, pp. 1889-1898
-
-
Afdhal, N.1
Zeuzem, S.2
Kwo, P.3
Chojkier, M.4
Gitlin, N.5
Puoti, M.6
Romero-Gomez, M.7
Zarski, J.P.8
Agarwal, K.9
Buggisch, P.10
-
24
-
-
84898669547
-
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection
-
Afdhal, N.; Reddy, K.R.; Nelson, D.R.; Lawitz, E.; Gordon, S.C.; Schiff, E.; Nahass, R.; Ghalib, R.; Gitlin, N.; Herring, R.; et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N. Engl. J. Med. 2014, 370, 1483–1493.
-
(2014)
N. Engl. J. Med.
, vol.370
, pp. 1483-1493
-
-
Afdhal, N.1
Reddy, K.R.2
Nelson, D.R.3
Lawitz, E.4
Gordon, S.C.5
Schiff, E.6
Nahass, R.7
Ghalib, R.8
Gitlin, N.9
Herring, R.10
-
25
-
-
84900326091
-
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.
-
Kowdley, K.V.; Gordon, S.C.; Reddy, K.R.; Rossaro, L.; Bernstein, D.E.; Lawitz, E.; Shiffman, M.L.; Schiff, E.; Ghalib, R.; Ryan, M; et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N. Engl. J. Med. 2014, 370, 1879–1888.
-
(2014)
N. Engl. J. Med.
, vol.370
, pp. 1879-1888
-
-
Kowdley, K.V.1
Gordon, S.C.2
Reddy, K.R.3
Rossaro, L.4
Bernstein, D.E.5
Lawitz, E.6
Shiffman, M.L.7
Schiff, E.8
Ghalib, R.9
Ryan, M.10
-
26
-
-
84928208414
-
Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation
-
Forns, X.; Charlton, M.; Denning, J.; McHutchison, J.G.; Symonds, W.T.; Brainard, D.; Brandt-Sarif, T.; Chang, P.; Kivett, V.; Castells, L.; et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology 2015, 61, 1485–1494.
-
(2015)
Hepatology
, vol.61
, pp. 1485-1494
-
-
Forns, X.1
Charlton, M.2
Denning, J.3
McHutchison, J.G.4
Symonds, W.T.5
Brainard, D.6
Brandt-Sarif, T.7
Chang, P.8
Kivett, V.9
Castells, L.10
-
27
-
-
84919360641
-
An interferon-free antiviral regimen for HCV after liver transplantation.
-
Kwo, P.Y.; Mantry, P.S.; Coakley, E.; Te, H.S.; Vargas, H.E.; Brown, R., Jr.; Gordon, F.; Levitsky, J.; Terrault, N.A.; Burton, J.R.; et al. An interferon-free antiviral regimen for HCV after liver transplantation. N. Engl. J. Med. 2014, 371, 2375–2382.
-
(2014)
N. Engl. J. Med.
, vol.371
, pp. 2375-2382
-
-
Kwo, P.Y.1
Mantry, P.S.2
Coakley, E.3
Te, H.S.4
Vargas, H.E.5
Brown, R.6
Gordon, F.7
Levitsky, J.8
Terrault, N.A.9
Burton, J.R.10
-
28
-
-
84922879130
-
.
-
Charlton, M.; Gane, E.; Manns, M.P.; Brown, R.S., Jr.; Curry, M.P.; Kwo, P.Y.; Fontana, R.J.; Gilroy, R.; Teperman, L.; Muir, A.J.; et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2015, 148, 108–117.
-
(2015)
Gastroenterology
, vol.148
, pp. 108-117
-
-
Charlton, M.1
Gane, E.2
Manns, M.P.3
Brown, R.S.4
Curry, M.P.5
Kwo, P.Y.6
Fontana, R.J.7
Gilroy, R.8
Teperman, L.9
Muir, A.J.10
-
29
-
-
84938953785
-
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients with Advanced Liver Disease
-
Charlton, M.; Everson, G.T.; Flamm, S.L.; Kumar, P.; Landis, C.; Brown, R.S., Jr.; Fried, M.W.; Terrault, N.A.; O’Leary, J.G.; Vargas, H.E.; et al. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients with Advanced Liver Disease. Gastroenterology 2015, 149, 649–659.
-
(2015)
Gastroenterology
, vol.149
, pp. 649-659
-
-
Charlton, M.1
Everson, G.T.2
Flamm, S.L.3
Kumar, P.4
Landis, C.5
Brown, R.S.6
Fried, M.W.7
Terrault, N.A.8
O’Leary, J.G.9
Vargas, H.E.10
-
30
-
-
84929582082
-
Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant
-
Pungpapong, S.; Aqel, B.; Leise, M.; Werner, K.T.; Murphy, J.L.; Henry, T.M.; Ryland, K.; Chervenak, A.E.; Watt, K.D.; Vargas, H.E.; et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology 2015, 61, 1880–1886.
-
(2015)
Hepatology
, vol.61
, pp. 1880-1886
-
-
Pungpapong, S.1
Aqel, B.2
Leise, M.3
Werner, K.T.4
Murphy, J.L.5
Henry, T.M.6
Ryland, K.7
Chervenak, A.E.8
Watt, K.D.9
Vargas, H.E.10
-
31
-
-
84940582565
-
Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy.
-
Yoshimi, S.; Imamura, M.; Murakami, E.; Hiraga, N.; Tsuge, M.; Kawakami, Y.; Aikata, H.; Abe, H.; Hayes, C.N.; Sasaki, T.; et al. Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy. J. Med. Virol. 2015, 87, 1913–1920.
-
(2015)
J. Med. Virol.
, vol.87
, pp. 1913-1920
-
-
Yoshimi, S.1
Imamura, M.2
Murakami, E.3
Hiraga, N.4
Tsuge, M.5
Kawakami, Y.6
Aikata, H.7
Abe, H.8
Hayes, C.N.9
Sasaki, T.10
-
32
-
-
84898990930
-
New hepatitis C therapies: The toolbox, strategies, and challenges
-
Pawlotsky, J.M. New hepatitis C therapies: The toolbox, strategies, and challenges. Gastroenterology 2014, 146, 1176–1192.
-
(2014)
Gastroenterology
, vol.146
, pp. 1176-1192
-
-
Pawlotsky, J.M.1
-
33
-
-
84903701056
-
-
. Update on hepatitis C virus resistance to direct-acting antiviral agents
-
Poveda, E.; Wyles, D.L.; Mena, A.; Pedreira, J.D.; Castro-Iglesias, A.; Cachay, E. Update on hepatitis C virus resistance to direct-acting antiviral agents. Antivir. Res. 2014, 108, 181–191.
-
(2014)
Antivir. Res
, vol.108
, pp. 181-191
-
-
Poveda, E.1
Wyles, D.L.2
Mena, A.3
Pedreira, J.D.4
Castro-Iglesias, A.5
Cachay, E.6
-
34
-
-
84906053496
-
.
-
Jacobson, I.M.; Dore, G.J.; Foster, G.R.; Fried, M.W.; Radu, M.; Rafalsky, V.V.; Moroz, L.; Craxi, A.; Peeters, M.; Lenz, O.; et al.. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): A phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014, 384, 403–413.
-
(2014)
Lancet
, vol.384
, pp. 403-413
-
-
Jacobson, I.M.1
Dore, G.J.2
Foster, G.R.3
Fried, M.W.4
Radu, M.5
Rafalsky, V.V.6
Moroz, L.7
Craxi, A.8
Peeters, M.9
Lenz, O.10
-
35
-
-
84873604286
-
Antiviral resistance and the future landscape of hepatitis C virus infection therapy.
-
Wyles, D.L. Antiviral resistance and the future landscape of hepatitis C virus infection therapy. J. Infect. Dis. 2013, 207 (Suppl. 1), S33–S39.
-
(2013)
J. Infect. Dis
, vol.207
, pp. S33-S39
-
-
Wyles, D.L.1
-
36
-
-
84880931245
-
.
-
Karino, Y.; Toyota, J.; Ikeda, K.; Suzuki, F.; Chayama, K.; Kawakami, Y.; Ishikawa, H.; Watanabe, H.; Hernandez, D.; Yu, F.; et al.. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J. Hepatol. 2013, 58, 646–654.
-
(2013)
J. Hepatol
, vol.58
, pp. 646-654
-
-
Karino, Y.1
Toyota, J.2
Ikeda, K.3
Suzuki, F.4
Chayama, K.5
Kawakami, Y.6
Ishikawa, H.7
Watanabe, H.8
Hernandez, D.9
Yu, F.10
-
37
-
-
84922879093
-
. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: An open-label study.
-
Curry, M.P.; Forns, X.; Chung, R.T.; Terrault, N.A.; Brown, R., Jr.; Fenkel, J.M.; Gordon, F.; O’Leary, J.; Kuo, A.; Schiano, T.; et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: An open-label study. Gastroenterology 2015, 148, 100.e1–107.e1.
-
(2015)
Gastroenterology
, vol.148
, pp. 100.e1-107.e1
-
-
Curry, M.P.1
Forns, X.2
Chung, R.T.3
Terrault, N.A.4
Brown, R.5
Fenkel, J.M.6
Gordon, F.7
O’Leary, J.8
Kuo, A.9
Schiano, T.10
-
38
-
-
84883219967
-
Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir
-
McPhee, F.; Hernandez, D.; Yu, F.; Ueland, J.; Monikowski, A.; Carifa, A.; Falk, P.; Wang, C.; Fridell, R.; Eley, T.; et al. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir. Hepatology 2013, 58, 902–911.
-
(2013)
Hepatology
, vol.58
, pp. 902-911
-
-
McPhee, F.1
Hernandez, D.2
Yu, F.3
Ueland, J.4
Monikowski, A.5
Carifa, A.6
Falk, P.7
Wang, C.8
Fridell, R.9
Eley, T.10
-
39
-
-
84898663922
-
Daclatasvir plus sofosbuvir for HCV infection
-
Sulkowski, M.S.; Jacobson, I.M.; Nelson, D.R. Daclatasvir plus sofosbuvir for HCV infection. N. Engl. J. Med. 2014, 370, 1560–1561.
-
(2014)
N. Engl. J. Med
, vol.370
, pp. 1560-1561
-
-
Sulkowski, M.S.1
Jacobson, I.M.2
Nelson, D.R.3
-
40
-
-
84925362379
-
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: A randomised, double-blind, phase 2 trial (SIRIUS)
-
Bourliere, M.; Bronowicki, J.P.; de Ledinghen, V.; Hezode, C.; Zoulim, F.; Mathurin, P.; Tran, A.; Larrey, D.G.; Ratziu, V.; Alric, L.; et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: A randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect. Dis. 2015, 15, 397–404.
-
(2015)
Lancet Infect. Dis
, vol.15
, pp. 397-404
-
-
Bourliere, M.1
Bronowicki, J.P.2
De Ledinghen, V.3
Hezode, C.4
Zoulim, F.5
Mathurin, P.6
Tran, A.7
Larrey, D.G.8
Ratziu, V.9
Alric, L.10
-
41
-
-
84925607745
-
Virological response after 6 week triple-drug regimens for hepatitis C: A proof-of-concept phase 2A cohort study
-
Kohli, A.; Osinusi, A.; Sims, Z.; Nelson, A.; Meissner, E.G.; Barrett, L.L.; Bon, D.; Marti, M.M.; Silk, R.; Kobt, C.; et al. Virological response after 6 week triple-drug regimens for hepatitis C: A proof-of-concept phase 2A cohort study. Lancet 2015, 385, 1107–1113.
-
(2015)
Lancet
, vol.385
, pp. 1107-1113
-
-
Kohli, A.1
Osinusi, A.2
Sims, Z.3
Nelson, A.4
Meissner, E.G.5
Barrett, L.L.6
Bon, D.7
Marti, M.M.8
Silk, R.9
Kobt, C.10
-
42
-
-
84931560807
-
Electronic address eee. EASL Recommendations on Treatment of Hepatitis C 2015
-
European Association for the Study of the Liver. Electronic address eee. EASL Recommendations on Treatment of Hepatitis C 2015. J. Hepatol. 2015, 63, 199–236.
-
(2015)
J. Hepatol
, vol.63
, pp. 199-236
-
-
-
43
-
-
84875695802
-
. Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: A randomized controlled study.
-
Chung, R.T.; Gordon, F.D.; Curry, M.P.; Schiano, T.D.; Emre, S.; Corey, K.; Markmann, J.F.; Herti, M.; Pomposelli, J.J.; Pomfret, E.A.; et al. Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: A randomized controlled study. Am. J. Transplant. 2013, 13, 1047–1054.
-
(2013)
Am. J. Transplant.
, vol.13
, pp. 1047-1054
-
-
Chung, R.T.1
Gordon, F.D.2
Curry, M.P.3
Schiano, T.D.4
Emre, S.5
Corey, K.6
Markmann, J.F.7
Herti, M.8
Pomposelli, J.J.9
Pomfret, E.A.10
-
44
-
-
84929160912
-
.. Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody
-
Mailly, L.; Xiao, F.; Lupberger, J.; Wilson, G.K.; Aubert, P.; Duong, F.H.; Calabrese, D.; Leboeuf, C.; Fofana, I.; Thumann, C.; et al. Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody. Nat. Biotechnol. 2015, 33, 549–554.
-
(2015)
Nat. Biotechnol
, vol.33
, pp. 549-554
-
-
Mailly, L.1
Xiao, F.2
Lupberger, J.3
Wilson, G.K.4
Aubert, P.5
Duong, F.H.6
Calabrese, D.7
Leboeuf, C.8
Fofana, I.9
Thumann, C.10
-
45
-
-
84913554793
-
HCV animal models and liver disease
-
Vercauteren, K.; de Jong, Y.P.; Meuleman, P. HCV animal models and liver disease. J. Hepatol. 2014, 61, S26–S33.
-
(2014)
J. Hepatol
, vol.61
, pp. S26-S33
-
-
Vercauteren, K.1
De Jong, Y.P.2
Meuleman, P.3
-
46
-
-
0035077063
-
.. Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment
-
Mazzaferro, V.; Tagger, A.; Schiavo, M.; Regalia, E.; Pulvirenti, A.; Ribero, M.L.; Coppa, J.; Romito, R.; Burgoa, L.; Zucchini, N.; et al. Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. Transplant. Proc. 2001, 33, 1355–1357.
-
(2001)
Transplant. Proc
, vol.33
, pp. 1355-1357
-
-
Mazzaferro, V.1
Tagger, A.2
Schiavo, M.3
Regalia, E.4
Pulvirenti, A.5
Ribero, M.L.6
Coppa, J.7
Romito, R.8
Burgoa, L.9
Zucchini, N.10
-
47
-
-
19944430229
-
.
-
Chalasani, N.; Manzarbeitia, C.; Ferenci, P.; Vogel, W.; Fontana, R.J.; Voigt, M.; Riely, C.; Martin, P.; Teperman, L.; Jiao, J.; et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: Two randomized, controlled trials. Hepatology 2005, 41, 289–298.
-
(2005)
Hepatology
, vol.41
, pp. 289-298
-
-
Chalasani, N.1
Manzarbeitia, C.2
Ferenci, P.3
Vogel, W.4
Fontana, R.J.5
Voigt, M.6
Riely, C.7
Martin, P.8
Teperman, L.9
Jiao, J.10
-
48
-
-
79955060448
-
PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus
-
Bzowej, N.; Nelson, D.R.; Terrault, N.A.; Everson, G.T.; Teng, L.L.; Prabhakar, A.; Charlton, M.R. PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transplant. 2011, 17, 528–538.
-
(2011)
Liver Transplant
, vol.17
, pp. 528-538
-
-
Bzowej, N.1
Nelson, D.R.2
Terrault, N.A.3
Everson, G.T.4
Teng, L.L.5
Prabhakar, A.6
Charlton, M.R.7
-
49
-
-
11844249361
-
Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation
-
Shergill, A.K.; Khalili, M.; Straley, S.; Bollinger, K.; Roberts, J.P.; Ascher, N.A.; Terrault, N.A. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am. J. Transplant. 2005, 5, 118–124.
-
(2005)
Am. J. Transplant
, vol.5
, pp. 118-124
-
-
Shergill, A.K.1
Khalili, M.2
Straley, S.3
Bollinger, K.4
Roberts, J.P.5
Ascher, N.A.6
Terrault, N.A.7
-
50
-
-
8644222054
-
Preemptive therapy for hepatitis C virus after living-donor liver transplantation
-
Sugawara, Y.; Makuuchi, M.; Matsui, Y.; Kishi, Y.; Akamatsu, N.; Kaneko, J.; Kokudo, N. Preemptive therapy for hepatitis C virus after living-donor liver transplantation. Transplantation 2004, 78, 1308–1311.
-
(2004)
Transplantation
, vol.78
, pp. 1308-1311
-
-
Sugawara, Y.1
Makuuchi, M.2
Matsui, Y.3
Kishi, Y.4
Akamatsu, N.5
Kaneko, J.6
Kokudo, N.7
-
51
-
-
73449143487
-
Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation
-
Carrion, J.A.; Torres, F.; Crespo, G.; Miquel, R.; Garcia-Valdecasas, J.C.; Navasa, M.; Forns, X. Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation. Hepatology 2010, 51, 23–34.
-
(2010)
Hepatology
, vol.51
, pp. 23-34
-
-
Carrion, J.A.1
Torres, F.2
Crespo, G.3
Miquel, R.4
Garcia-Valdecasas, J.C.5
Navasa, M.6
Forns, X.7
-
52
-
-
33645227469
-
Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation
-
Blasco, A.; Forns, X.; Carrion, J.A.; Garcia-Pagan, J.C.; Gilabert, R.; Rimola, A.; Miquel, R.; Bruguera, M.; Garcia-Valdecasas, J.C.; Bosch, J.; et al Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology 2006, 43, 492–499.
-
(2006)
Hepatology
, vol.43
, pp. 492-499
-
-
Blasco, A.1
Forns, X.2
Carrion, J.A.3
Garcia-Pagan, J.C.4
Gilabert, R.5
Rimola, A.6
Miquel, R.7
Bruguera, M.8
Garcia-Valdecasas, J.C.9
Bosch, J.10
-
53
-
-
58249086156
-
Hepatitis C virus therapy in liver transplant recipients: Response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis
-
Roche, B.; Sebagh, M.; Canfora, M.L.; Antonini, T.; Roque-Afonso, A.M.; Delvart, V.; Saliba, F.; Duclos-Vallee, J.C.; Castaing, D.; Samuel, D. Hepatitis C virus therapy in liver transplant recipients: Response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transplant. 2008, 14, 1766–1777.
-
(2008)
Liver Transplant
, vol.14
, pp. 1766-1777
-
-
Roche, B.1
Sebagh, M.2
Canfora, M.L.3
Antonini, T.4
Roque-Afonso, A.M.5
Delvart, V.6
Saliba, F.7
Duclos-Vallee, J.C.8
Castaing, D.9
Samuel, D.10
-
54
-
-
33745343818
-
Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: A review and quantitative analysis
-
Wang, C.S.; Ko, H.H.; Yoshida, E.M.; Marra, C.A.; Richardson, K. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: A review and quantitative analysis. Am. J. Transplant. 2006, 6, 1586–1599.
-
(2006)
Am. J. Transplant
, vol.6
, pp. 1586-1599
-
-
Wang, C.S.1
Ko, H.H.2
Yoshida, E.M.3
Marra, C.A.4
Richardson, K.5
-
55
-
-
52149121573
-
Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: Systematic review and meta-analysis of prospective controlled studies
-
Xirouchakis, E.; Triantos, C.; Manousou, P.; Sigalas, A.; Calvaruso, V.; Corbani, A.; Leandro, G.; Patch, D.; Burroughs, A. Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: Systematic review and meta-analysis of prospective controlled studies. J. Viral Hepat. 2008, 15, 699–709.
-
(2008)
J. Viral Hepat
, vol.15
, pp. 699-709
-
-
Xirouchakis, E.1
Triantos, C.2
Manousou, P.3
Sigalas, A.4
Calvaruso, V.5
Corbani, A.6
Leandro, G.7
Patch, D.8
Burroughs, A.9
-
56
-
-
33745997054
-
Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C
-
Berenguer, M.; Palau, A.; Fernandez, A.; Benlloch, S.; Aguilera, V.; Prieto, M.; Rayon, J.M.; Berenguer, J. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transplant. 2006, 12, 1067–1076.
-
(2006)
Liver Transplant
, vol.12
, pp. 1067-1076
-
-
Berenguer, M.1
Palau, A.2
Fernandez, A.3
Benlloch, S.4
Aguilera, V.5
Prieto, M.6
Rayon, J.M.7
Berenguer, J.8
-
57
-
-
84939264571
-
.
-
Manns, M.; Forns, X.; Samuel, D.; Denning, J.; Arterburn, S.; Brandt-Sarif, T.; Dvory-Sobol, H.; Pang, P.S.; McHutchison, J.G.; Gane, E.; et al Ledipasvir/sofosbuvir with ribavirin is safe and efficacious in decompensated and post liver transplantation patients with HCV infection: Preliminary results of the prospective solar 2 trial. J. Hepatol. 2015, 62, S187–S188.
-
(2015)
J. Hepatol
, vol.62
, pp. S187-S188
-
-
Manns, M.1
Forns, X.2
Samuel, D.3
Denning, J.4
Arterburn, S.5
Brandt-Sarif, T.6
Dvory-Sobol, H.7
Pang, P.S.8
McHutchison, J.G.9
Gane, E.10
-
58
-
-
84936845723
-
Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or posttransplant recurrence: Phase 3 ALLY-1 study
-
Poordad, F.; Schiff, E.R.; Vierling, J.M.; Landis, C.; Fontana, R.J.; Yang, R.; McPhee, F.; Hughes, E.A.; Noviello, S.; Swenson, E.S. Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or posttransplant recurrence: Phase 3 ALLY-1 study. J. Hepatol. 2015, 62, S261–S262.
-
(2015)
J. Hepatol
, vol.62
, pp. S261-S262
-
-
Poordad, F.1
Schiff, E.R.2
Vierling, J.M.3
Landis, C.4
Fontana, R.J.5
Yang, R.6
McPhee, F.7
Hughes, E.A.8
Noviello, S.9
Swenson, E.S.10
-
59
-
-
84936846679
-
.. The association of sofosbuvir and daclatasvir for treating severe recurrence of HCV infection after liver transplantation: Results from a large french prospective multicentric ANRS CO23 CUPILT cohort
-
Coilly, A.; Fougerou, C.; de Ledinghen, V.; Houssel-Debry, P.; Duvoux, C.; di Martino, V.; Radenne, S.; Kamar, N.; d'Alteroche, L.; Leroy, V.; et al. The association of sofosbuvir and daclatasvir for treating severe recurrence of HCV infection after liver transplantation: Results from a large french prospective multicentric ANRS CO23 CUPILT cohort. J. Hepatol. 2015, 62, S236–S237.
-
(2015)
J. Hepatol
, vol.62
, pp. S236-S237
-
-
Coilly, A.1
Fougerou, C.2
De Ledinghen, V.3
Houssel-Debry, P.4
Duvoux, C.5
Di Martino, V.6
Radenne, S.7
Kamar, N.8
D'alteroche, L.9
Leroy, V.10
-
60
-
-
84928068548
-
Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir
-
Badri, P.; Dutta, S.; Coakley, E.; Cohen, D.; Ding, B.; Podsadecki, T.; Bernstein, B.; Awni, W.; Menon, R. Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. Am. J. Transplant. 2015, 15, 1313–1322.
-
(2015)
Am. J. Transplant
, vol.15
, pp. 1313-1322
-
-
Badri, P.1
Dutta, S.2
Coakley, E.3
Cohen, D.4
Ding, B.5
Podsadecki, T.6
Bernstein, B.7
Awni, W.8
Menon, R.9
-
61
-
-
84939653819
-
Hepatitis C Guidance: AASLD-IDSA Recommendations for Testing, Managing, and Treating Adults Infected with Hepatitis C Virus
-
AASLD/IDSA HCV Guidance Panel. Hepatitis C Guidance: AASLD-IDSA Recommendations for Testing, Managing, and Treating Adults Infected with Hepatitis C Virus. Hepatology 2015, 62, 932–954.
-
(2015)
Hepatology
, vol.62
, pp. 932-954
-
-
-
62
-
-
84944279226
-
Efficacy of Sofosbuvir and Daclatasvir in Patients with Fibrosing Cholestatic Hepatitis C After Liver Transplantation
-
in press
-
Leroy, V.; Dumortier J.; Coilly A.; Sebagh, M.; Fougerou-Leurent, C.; Radenne, S.; Botta, D.; Durand, F.; Silvain, C.; Lebray, P.; et al. Efficacy of Sofosbuvir and Daclatasvir in Patients with Fibrosing Cholestatic Hepatitis C After Liver Transplantation. Clin. Gastroenterol. Hepatol. 2015. in press.
-
(2015)
Clin. Gastroenterol. Hepatol
-
-
Leroy, V.1
Dumortier, J.2
Coilly, A.3
Sebagh, M.4
Fougerou-Leurent, C.5
Radenne, S.6
Botta, D.7
Durand, F.8
Silvain, C.9
Lebray, P.10
-
63
-
-
84942437304
-
-
online, (accessed on 1 June 2015)
-
University of Liverpool. Hep-Druginteractions [online]. 2015. Available online: www.hep-druginteractions.org (accessed on 1 June 2015).
-
(2015)
Hep-Druginteractions
-
-
-
65
-
-
84942413675
-
The pharmacokinetics of Ledipasvir, an HCV specific NS5A inhibitor in HCV-uninfected subjects with moderate and severe hepatic impairement
-
German-Polina, A.M.; Yang, J.C.; McNair, L.; Shen, G. The pharmacokinetics of Ledipasvir, an HCV specific NS5A inhibitor in HCV-uninfected subjects with moderate and severe hepatic impairement. Hepatology 2013.
-
(2013)
Hepatology
-
-
German-Polina, A.M.1
Yang, J.C.2
McNair, L.3
Shen, G.4
-
66
-
-
84863641361
-
Pharmacokinetics of TMC 435 in subjects with moderate hepatic impairment.
-
Sekar, V.; Simion, A.; Peeters, M.; Spittaels, K.; Lawitz, E.; Marbury, T.C.; de Smedt, G. Pharmacokinetics of TMC 435 in subjects with moderate hepatic impairment. J. Hepatol. 2011.
-
(2011)
J. Hepatol
-
-
Sekar, V.1
Simion, A.2
Peeters, M.3
Spittaels, K.4
Lawitz, E.5
Marbury, T.C.6
De Smedt, G.7
-
67
-
-
84899736863
-
Pharmacokinetics and safety of co-administered ABT-450 plus ritonavir (ABT 450/r), ABT 267, and ABT 333 as a single dose in subjects with normal hepatic function and in subjects with mild, moderate and severe hepatic impairment
-
Khatri, A.; Gaultier, I.A.; Menon, R.; Marbury, T.C.; Lawitz, E.; Podsadecki, T.J.; Mullally, V.; Awni, W.M.; Bernstein, B.; Dutta, S. Pharmacokinetics and safety of co-administered ABT-450 plus ritonavir (ABT 450/r), ABT 267, and ABT 333 as a single dose in subjects with normal hepatic function and in subjects with mild, moderate and severe hepatic impairment. Hepatology 2012.
-
(2012)
Hepatology
-
-
Khatri, A.1
Gaultier, I.A.2
Menon, R.3
Marbury, T.C.4
Lawitz, E.5
Podsadecki, T.J.6
Mullally, V.7
Awni, W.M.8
Bernstein, B.9
Dutta, S.10
-
68
-
-
84871137756
-
Single-dose pharmacokinetics of daclatasvir (DCV; BMS-790052) in subjects with hepatic impairment compared with healthy subjects
-
Bifano, M.; Sevinsky, H.; Persson, A.; Chung, E.; Wind-Rotolo, M.; Hwang, C.; Nettles, R.; Grasela, D.; Marbury, T.; Marbury, T.; et al. single-dose pharmacokinetics of daclatasvir (DCV; BMS-790052) in subjects with hepatic impairment compared with healthy subjects. Hepatology 2011.
-
(2011)
Hepatology
-
-
Bifano, M.1
Sevinsky, H.2
Persson, A.3
Chung, E.4
Wind-Rotolo, M.5
Hwang, C.6
Nettles, R.7
Grasela, D.8
Marbury, T.9
Marbury, T.10
-
69
-
-
84856044809
-
Education by a nurse increases the adherence to therapy in chronic hepatitis C patients
-
Alavian, S.M.; Aalaei-Andabili, S.H. Education by a nurse increases the adherence to therapy in chronic hepatitis C patients. Clin. Gastroenterol. Hepatol. 2012, 10, 203.
-
(2012)
Clin. Gastroenterol. Hepatol
, vol.10
-
-
Alavian, S.M.1
Aalaei-Andabili, S.H.2
|